左甲状腺素对晚期CKD患者蛋白尿影响的初步试验
这项单中心、双盲、随机、安慰剂对照初步试验纳入32例晚期蛋白尿性CKD患者,基线已使用ACEI或ARB。左甲状腺素组12周时蛋白尿较安慰剂组显著下降1.1 g/d(P=0.0011),eGFR改善4 ml/min/1.73 m2(P=0.049)。
要点
- 对TSH处于低亚临床甲减范围的晚期CKD患者,左甲状腺素可降低蛋白尿。
- 左甲状腺素组eGFR较安慰剂组改善4 ml/min/1.73 m2(P=0.049)。
- 不良反应两组相近,无因不良反应退出或严重不良事件。
核心结论
- 在已使用ACEI或ARB的晚期蛋白尿性CKD患者中,左甲状腺素使TSH接近2.5 μIU/ml可降低蛋白尿并改善eGFR。
研究设计与样本
- 单中心、双盲、随机、安慰剂对照初步临床试验,共随机32例蛋白尿性CKD患者(eGFR<60 ml/min/1.73 m2且蛋白尿>150 mg/d)。
- 干预为左甲状腺素或安慰剂12周,目标TSH范围1.25-2.5 μIU/l,入组TSH为2.6-9.9 μIU/ml且FT4在0.7-1.8 ng/dl。
主要发现
- 12周时左甲状腺素组蛋白尿为0.89±1.28 g/d,安慰剂组为1.35±0.85 g/d,左甲状腺素较安慰剂显著降低蛋白尿1.1 g/d(P=0.0011)。
- 左甲状腺素组eGFR改善4 ml/min/1.73 m2(P=0.049),安慰剂组eGFR下降1.98 ml/min/1.73 m2。
- 两组血清肌酐、胆固醇、甘油三酯、LDL、收缩压和舒张压无差异。
- 左甲状腺素组不良事件报告率7.14%,安慰剂组11.11%,无因不良反应退出研究,无严重不良事件。
关键数值与推荐
- 入组标准:eGFR<60 ml/min/1.73 m2且蛋白尿>150 mg/d,TSH 2.6-9.9 μIU/ml,FT4 0.7-1.8 ng/dl。
- 主要目标为比较研究开始与结束时蛋白尿绝对水平;次要目标包括血清肌酐、eGFR、胆固醇、甘油三酯、LDL、血压变化及安全耐受性。
临床怎么用
- 对于晚期蛋白尿性CKD且TSH处于低亚临床甲减范围、已使用ACEI或ARB的患者,可考虑左甲状腺素治疗以降低蛋白尿并改善eGFR。
- 治疗目标可将TSH调整至接近2.5 μIU/ml,需监测不良反应。
局限性
- 单中心、小样本初步试验,结果需未来研究证实。
- 结论不能外推至未明确入组本试验的患者群体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Thyroid hormones can directly affect kidney function; elevated levels of thyroid-stimulating hormone (TSH) and chronic kidney disease (CKD) are associated with proteinuria, decreased estimated glomerular filtration rate (eGFR), and progression to end-stage renal disease. Our hypothesis is that in patients with CKD and TSH at levels considered to be in the low subclinical hypothyroidism (SCH) range, lowering TSH with levothyroxine (LVX) improves the clinical parameters of renal function. METHODS: This was a double-blind, randomized, pilot clinical trial in patients with proteinuric CKD (eGFR <60 ml/min per 1.73 m2 and proteinuria >150 mg/d) performed at the Hospital Civil de Guadalajara, with the intention of lowering TSH (levels of 1.25-2.5 μIU/l) in patients with TSH (levels of 2.6-9.9 μIU/ml with FT4 in the range of 0.7-1.8 ng/dl). Patients were randomized 1:1 to receive LVX or placebo for 12 weeks. The primary objective was to evaluate absolute levels of proteinuria at the beginning compared to the end of the study and, as a secondary objective, the changes in serum creatinine (sCr), eGFR, cholesterol, triglycerides, low-density lipoprotein (LDL), and blood pressure, and to assess the tolerability and safety of LVX. RESULTS: Between March and November 2018, a total of 163 patients were assessed for eligibility; 119 patients did not meet the inclusion criteria or were excluded, and 32 patients were randomized. The demographic and clinical characteristics of the 2 study groups were essentially not different. Subjects were 66.87 (SD 12.19) years of age, 62.5% were female, 75% were diabetes mellitus, eGFR was 23.55 (±12.91) ml/min per 1.73 m2, TSH was 5.37 ± 2.13 μIU/ml, proteinuria in 24-hour urine collection was 1.52 ± 1.12, and all of them were taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs). Proteinuria at 12 weeks in the LVX group was 0.89 SD ± 1.28 g/d, and in the placebo group it was 1.35 SD ± 0.85 g/d; when compared to placebo, LVX showed a significant decrease in proteinuria of 1.1 g/d (P = 0.0011). The eGFR in the LVX group showed an improvement of 4 ml/min/1.73 m2 (P = 0.049); in the placebo group, there was a decrease of 1.98 ml/min per 1.73 m2. The sCr, cholesterol, triglycerides, low-density lipoprotein, systolic blood pressure, and diastolic blood pressure were not different between groups. Adverse events were reported in the LVX group in 7.14% of patients and in 11.11% of patients in the placebo group; none left the study because of adverse effects, and there were no serious adverse events. CONCLUSION: This single-center, randomized, double-blind, placebo-controlled pilot clinical trial in patients with advanced proteinuric CKD who already used ACEIs or ARBs demonstrated that administering LVX to obtain a TSH range close to 2.5 μIU/ml decreased proteinuria and improved eGFR. Future research is needed to confirm our results and to determine whether our findings generalize to patient groups not explicitly enrolled in this small pilot trial.
引用
- Blackaller GN, Chávez-Iñiguez JS, Carreón-Bautista EE, et al. A Pilot Trial on the Effect of Levothyroxine on Proteinuria in Patients With Advanced CKD. Kidney Int Rep. 2020. PMID: 33426390. doi:10.1016/j.ekir.2020.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。